ResoundingHealth
Search
  
Basic Drug Info
Drug Name:URISPAS
Manufacturer:ORTHO-McNEIL PHARMACEUTICAL, INC.
Other Info:

One or two 100 mg tablets 3 or 4 times a day.

With improvement of symptoms, the dose may be reduced.

This drug cannot be recommended for infants and children under 12 years of age because safety and efficacy have not been demonstrated in this age group.



Clinical Trials:


Indications and Usage

URISPAS® (flavoxate HCl) is indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

URISPAS® is not indicated for definitive treatment, but is compatible with drugs used for the treatment of urinary tract infections.
Dysuria -- Painful URINATION. It is often associated with infections of the lower URINARY TRACT.

Nocturia -- Frequent URINATION at night that interrupts sleep. It is often associated with outflow obstruction, DIABETES MELLITUS, or bladder inflammation (CYSTITIS).

Incontinence --

Urinary Incontinence -- Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.

Cystitis -- Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.

prostatitis -- Prostatitis: inflammation of the prostate, appreciated clinically as an enlarged, soft or tender prostate. Prostatic secretions contain large numbers of leukocytes.

Nonspecific urethritis --

Urethritis -- Inflammation involving the URETHRA. Similar to CYSTITIS, clinical symptoms range from vague discomfort to painful urination (DYSURIA), urethral discharge, or both.

Urinary tract infection -- Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.

Contraindications
URISPAS® (flavoxate HCl) is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.
Duodenal Obstruction -- Hindrance of the passage of luminal contents in the DUODENUM. Duodenal obstruction can be partial or complete, and caused by intrinsic or extrinsic factors. Simple obstruction is associated with diminished or stopped flow of luminal contents. Strangulating obstruction is associated with impaired blood flow to the duodenum in addition to obstructed flow of luminal contents.

Ileus -- A condition caused by the lack of intestinal PERISTALSIS or INTESTINAL MOTILITY without any mechanical obstruction. This interference of the flow of INTESTINAL CONTENTS often leads to INTESTINAL OBSTRUCTION. Ileus may be classified into postoperative, inflammatory, metabolic, neurogenic, and drug-induced.

Esophageal achalasia -- A motility disorder of the ESOPHAGUS in which the LOWER ESOPHAGEAL SPHINCTER (near the CARDIA) fails to relax resulting in functional obstruction of the esophagus, and DYSPHAGIA. Achalasia is characterized by a grossly contorted and dilated esophagus (megaesophagus).

Gastrointestinal Hemorrhage -- Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.

Obstructive Uropathy --

Warnings
URISPAS® (flavoxate HCl) should be given cautiously in patients with suspected glaucoma.

This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor. It should not to be used for self-diagnosis or treatment.